Amgen

Abstract modern white spiral clock dial with roman and arabic numerals
Biotech

Lilly links lepodisiran to durably lower lipoprotein in phase 2

Lilly saw sustained reductions for nearly 1.5 years, bolstering its argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.
Nick Paul Taylor Mar 31, 2025 4:24am
rocket launch satellite space fly blast off

Amgen ignites Rocket program with wins in phase 3 eczema trials

Mar 10, 2025 5:48am
chop down cut tree chainsaw ax

Amgen, CytomX ax T-cell engager after assessing data, priorities

Mar 7, 2025 5:39am
boat cutting through water

Amgen’s late-stage obesity trials expected to read out in ‘27

Mar 5, 2025 1:58pm
cancel

Amgen and Ideaya ax cancer combination trial

Feb 13, 2025 7:34am
FDA stop sign

Amgen's early-stage obesity asset put on clinical hold by FDA

Feb 4, 2025 6:13pm